Seung Yup Chu

This inventor holds 53 USPTO granted patents and 29 published patent applications, plus 5 CIPO patents and 16 EPO patents, primarily in Bispecific Antibodies. Top assignee: Xencor, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seung Yup Chu. Retrieved from https://idiyas.com/inventor/seung-yup-chu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 29)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 5.2

ph-index = 10

Forward Citations = 466(Granted Patents)

Forward Citations (Not Self Cited) = 309(Dec 10, 2025)

Location History:

Upland, CA (US) (2011 - 2023)
Cypress, CA (US) (2011 - 2024)

Company Filing History:

53 out of 227

Xencor, Inc.

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Heterodimeric Antibodies

IgE-Mediated Disorders

CD3 Targeting

CD38 Inhibition

Tumor Antigens

T Cell Modulation

CD32B Inhibition

Fibroblast Activation Protein

Trispecific Antibodies

CD19 Targeting

Regulatory T Cells

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559572 - NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS (2026-02-24),

2. 12497457 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-16),

3. 12398207 - Heterodimeric antibodies that bind CD3 and CLDN6 (2025-08-26),

4. 12359002 - Heterodimeric antibodies that bind CD3 and tumor antigens (2025-07-15),

5. 12180302 - Heterodimeric antibodies that bind fibroblast activation protein (2024-12-31),

6. 12129309 - Heterodimeric antibodies that bind CD3 and CD38 (2024-10-29),

7. 11945880 - Heterodimeric antibodies that bind CD3 and tumor antigens (2024-04-02),

8. 11859011 - Heterodimeric antibodies that bind CD3 and tumor antigens (2024-01-02),

9. 11840579 - Bispecific antibodies that bind to CD38 and CD3 (2023-12-12),

10. 11739144 - Heterodimeric antibodies that bind CD3 and CLDN6 (2023-08-29),

11. 11673972 - Heterodimeric antibodies that bind CD3 and tumor antigens (2023-06-13),

12. 11623957 - Heterodimeric antibodies that bind CD3 and PSMA (2023-04-11),

13. 11618788 - Optimized antibodies that target CD19 (2023-04-04),

14. 11566080 - Compositions and methods for treating IgE-mediated disorders (2023-01-31),

15. 11472890 - Heterodimeric antibodies that bind ENPP3 and CD3 (2022-10-18),

Title: The Innovative Journey of Seung Yup Chu

Introduction: Seung Yup Chu, a talented inventor hailing from Cypress, CA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Seung Yup Chu holds several patents in the areas of electronics and software development, with his most recent patent focusing on a cutting-edge artificial intelligence algorithm for autonomous vehicles.

Career Highlights: With a background in computer science and engineering, Seung Yup Chu has worked for top tech companies, leading research institutions, and universities, where he has spearheaded projects that have pushed the boundaries of technological advancement.

Collaborations: Throughout his career, Seung Yup Chu has collaborated with renowned experts in the industry, including fellow inventors, patent attorneys, and researchers, to bring his ideas to life and secure intellectual property rights for his innovations.

Conclusion: Seung Yup Chu's passion for innovation, coupled with his technical expertise and collaborative spirit, continues to drive him towards creating groundbreaking solutions that have the potential to shape the future of technology.

Profile summary based on public USPTO records.